FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965237299> ?p ?o ?g. }

• W2965237299 abstract "Doxorubicin is currently the most effective chemotherapeutic drug used to treat breast cancer. It has, however, been shown that doxorubicin can induce drug resistance resulting in poor patient prognosis and survival. Studies reported that the interaction between signalling pathways can promote drug resistance through the induction of proliferation, cell cycle progression and prevention of apoptosis. The aim of this study was therefore to determine the effects of doxorubicin on apoptosis signalling, autophagy, the mitogen-activated protein kinase (MAPK)- and phosphoinositide 3-kinase (PI3K)/Akt signalling pathway, cell cycle control, and regulators of the epithelial-mesenchymal transition (EMT) process in murine breast cancer tumours.A tumour-bearing mouse model was established by injecting murine E0771 breast cancer cells, suspended in Hank's Balances Salt Solution and Corning® Matrigel® Basement Membrane Matrix, into female C57BL/6 mice. Fourty-seven mice were randomly divided into three groups, namely tumour control (received Hank's Balances Salt Solution), low dose doxorubicin (received total of 6 mg/ml doxorubicin) and high dose doxorubicin (received total of 15 mg/ml doxorubicin) groups. A higher tumour growth rate was, however, observed in doxorubicin-treated mice compared to the untreated controls. We therefore compared the expression levels of markers involved in cell death and survival signalling pathways, by means of western blotting and fluorescence-based immunohistochemistry.Doxorubicin failed to induce cell death, by means of apoptosis or autophagy, and cell cycle arrest, indicating the occurrence of drug resistance and uncontrolled proliferation. Activation of the MAPK/ extracellular-signal-regulated kinase (ERK) pathway contributed to the resistance observed in treated mice, while no significant changes were found with the PI3K/Akt pathway and other MAPK pathways. Significant changes were also observed in cell cycle p21 and DNA replication minichromosome maintenance 2 proteins. No significant changes in EMT markers were observed after doxorubicin treatment.Our results suggest that doxorubicin-induced drug resistance and tumour growth can occur through the adaptive role of the MAPK/ERK pathway in an effort to protect tumour cells. Previous studies have shown that the efficacy of doxorubicin can be improved by inhibition of the ERK signalling pathway and thereby treatment failure can be overcome." @default.
• W2965237299 created "2019-08-13" @default.
• W2965237299 creator A5008409392 @default.
• W2965237299 creator A5009374111 @default.
• W2965237299 creator A5022813664 @default.
• W2965237299 creator A5029014057 @default.
• W2965237299 creator A5032412432 @default.
• W2965237299 creator A5067849519 @default.
• W2965237299 date "2019-08-01" @default.
• W2965237299 modified "2023-10-14" @default.
• W2965237299 title "Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model" @default.
• W2965237299 cites W1555772346 @default.
• W2965237299 cites W1977186103 @default.
• W2965237299 cites W1990161819 @default.
• W2965237299 cites W1993736136 @default.
• W2965237299 cites W1999929449 @default.
• W2965237299 cites W2017168362 @default.
• W2965237299 cites W2019727983 @default.
• W2965237299 cites W2030614165 @default.
• W2965237299 cites W2033346155 @default.
• W2965237299 cites W2050675499 @default.
• W2965237299 cites W2065919583 @default.
• W2965237299 cites W2072860434 @default.
• W2965237299 cites W2079351077 @default.
• W2965237299 cites W2080261745 @default.
• W2965237299 cites W2096772718 @default.
• W2965237299 cites W2104584000 @default.
• W2965237299 cites W2106952204 @default.
• W2965237299 cites W2124173308 @default.
• W2965237299 cites W2131186576 @default.
• W2965237299 cites W2132243179 @default.
• W2965237299 cites W2144169031 @default.
• W2965237299 cites W2154589460 @default.
• W2965237299 cites W2156010010 @default.
• W2965237299 cites W2157540307 @default.
• W2965237299 cites W2161954129 @default.
• W2965237299 cites W2170839629 @default.
• W2965237299 cites W2191849929 @default.
• W2965237299 cites W2513201069 @default.
• W2965237299 cites W2782012962 @default.
• W2965237299 cites W2917837889 @default.
• W2965237299 doi "https://doi.org/10.1186/s12885-019-5939-z" @default.
• W2965237299 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6670209" @default.
• W2965237299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31370818" @default.
• W2965237299 hasPublicationYear "2019" @default.
• W2965237299 type Work @default.
• W2965237299 sameAs 2965237299 @default.
• W2965237299 citedByCount "88" @default.
• W2965237299 countsByYear W29652372992020 @default.
• W2965237299 countsByYear W29652372992021 @default.
• W2965237299 countsByYear W29652372992022 @default.
• W2965237299 countsByYear W29652372992023 @default.
• W2965237299 crossrefType "journal-article" @default.
• W2965237299 hasAuthorship W2965237299A5008409392 @default.
• W2965237299 hasAuthorship W2965237299A5009374111 @default.
• W2965237299 hasAuthorship W2965237299A5022813664 @default.
• W2965237299 hasAuthorship W2965237299A5029014057 @default.
• W2965237299 hasAuthorship W2965237299A5032412432 @default.
• W2965237299 hasAuthorship W2965237299A5067849519 @default.
• W2965237299 hasBestOaLocation W29652372991 @default.
• W2965237299 hasConcept C121608353 @default.
• W2965237299 hasConcept C126322002 @default.
• W2965237299 hasConcept C184235292 @default.
• W2965237299 hasConcept C190283241 @default.
• W2965237299 hasConcept C203522944 @default.
• W2965237299 hasConcept C2776694085 @default.
• W2965237299 hasConcept C2781303535 @default.
• W2965237299 hasConcept C29537977 @default.
• W2965237299 hasConcept C31573885 @default.
• W2965237299 hasConcept C502942594 @default.
• W2965237299 hasConcept C530470458 @default.
• W2965237299 hasConcept C55493867 @default.
• W2965237299 hasConcept C57074206 @default.
• W2965237299 hasConcept C71924100 @default.
• W2965237299 hasConcept C75217442 @default.
• W2965237299 hasConcept C86803240 @default.
• W2965237299 hasConcept C95444343 @default.
• W2965237299 hasConcept C98274493 @default.
• W2965237299 hasConceptScore W2965237299C121608353 @default.
• W2965237299 hasConceptScore W2965237299C126322002 @default.
• W2965237299 hasConceptScore W2965237299C184235292 @default.
• W2965237299 hasConceptScore W2965237299C190283241 @default.
• W2965237299 hasConceptScore W2965237299C203522944 @default.
• W2965237299 hasConceptScore W2965237299C2776694085 @default.
• W2965237299 hasConceptScore W2965237299C2781303535 @default.
• W2965237299 hasConceptScore W2965237299C29537977 @default.
• W2965237299 hasConceptScore W2965237299C31573885 @default.
• W2965237299 hasConceptScore W2965237299C502942594 @default.
• W2965237299 hasConceptScore W2965237299C530470458 @default.
• W2965237299 hasConceptScore W2965237299C55493867 @default.
• W2965237299 hasConceptScore W2965237299C57074206 @default.
• W2965237299 hasConceptScore W2965237299C71924100 @default.
• W2965237299 hasConceptScore W2965237299C75217442 @default.
• W2965237299 hasConceptScore W2965237299C86803240 @default.
• W2965237299 hasConceptScore W2965237299C95444343 @default.
• W2965237299 hasConceptScore W2965237299C98274493 @default.
• W2965237299 hasFunder F4320320672 @default.
• W2965237299 hasFunder F4320322697 @default.
• W2965237299 hasFunder F4320333169 @default.
• W2965237299 hasIssue "1" @default.

• next